Company Overview and News
In a research report yesterday, Maybank Investment Bank Research (Maybank IB) said the deal with PNB - EPF was expected to be concluded by next month. “Sale of BPS2 commercial spaces to EPF-PNB would be concluded by July 2018 with earnings to be recognised upon completion of the BPS2 construction works between the fourth quarter of 2019 and third quarter of 2020.”
ONCE again, there is talk of a possible flotation of national oil company Petroliam Nasional Bhd (Petronas). Speculation about such a move makes the rounds every few years. Listing Petronas, it is said, could be one way to help cut down the country’s debt, which has breached the RM1 trillion mark, or a little more than 80% of gross domestic product.
5183 PECGF 4197 5681 6033 PNADF 5347 SMEBF TNABY TNABF BSMAF PNAGF 1818
KUALA LUMPUR, June 13 — Sime Darby Property and SP Setia today asserted that they had acquired Battersea Power Station (BPS) in the UK through “a competitive tender process”.
Trimmed down: The Ara Damansara Medical Centre, under Ramsay Sime Darby Health Care Group, is a modern centre that offers a wide range of rehabilitation services. Sime Darby’s business now lies mainly in the industrial, motor, logistics and healthcare segments.
RMYHY RHC SMEBF 4197 RMSYF
KUALA LUMPUR: Bursa Malaysia recorded the highest ever in trading value on Thursday at more than RM9bil as the FBM KLCI staged a steady rebound as the government unveiled more solid measures to strengthen the economy. At 5pm, the KLCI was up 21.34 points or 1.24% to 1,740.62. However, it managed to only recoup more than just one-third of the losses after falling more 56 points the previous day in a broad selloff.
PBLOF GMALF 4065 4197 5681 1295 6033 GMALY PNADF 4715 SMEBF 8869 5819 BSMAF PNAGF GEBHF 1818
Ajinomoto Co. is considering selling Amoy Food Ltd., the century-old company that makes Hong Kong’s most popular brand of soy sauce, according to people with knowledge of the matter.
HRL SMEBF 4197
AmBank Research said that in the reporting season this time around with two-thirds of companies in its universe already having released their results, only 9% had beaten its in-house profit projections. It added that 64% had met its in-house profit projections, while another 27% missed its targets.
Savills Malaysia managing director Datuk Paul Khong(inset pic) said improved market sentiment would certainly boost foreign direct industrial investment into Malaysia. (Picture shows A worker putting up a Savills estate agents sign in London, Britain, April 10, 2018. - Reuters
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HRL SMEBF 4197
KUALA LUMPUR: JF Apex Research expects MISC Bhd , Chemical Co of Malaysia Bhd (CCM), Malaysia Steel Works (KL) Bhd (Masteel), Power Root Bhd and Sime Darby Bhd to be among the stocks to watch on Monday.
SMEBF 4197 5098 7237
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
2018-06-11 - Asif
Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...